Immune cell cocktail takes on Platinum-Resistant ovarian cancer

NCT ID NCT06710288

Recruiting now Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This phase 2 trial tests a new approach for people with platinum-resistant high-grade ovarian cancer, a type that no longer responds to standard chemotherapy. Up to 20 participants will receive their own immune cells (M-CENK) that have been trained to fight cancer, along with an immune booster (N-803) and the chemotherapy drug gemcitabine. The goal is to see if this combination can shrink tumors or slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M-CENK (memory cytokine enriched natural killer cells), N-803 (IL-15 superagonist), and gemcitabine
What this could lead to: If it works, this could offer a new treatment option for people with ovarian cancer that no longer responds to platinum-based chemotherapy.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination therapy may cause side effects and may not shrink tumors or extend survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLATINUM-RESISTANT OVARIAN CANCER

Contacts and locations

Locations

Chan Soon-Shiong Institute for Medicine
RECRUITING

El Segundo, California, 90245, United States
Hoag
RECRUITING

Newport Beach, California, 92663, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.